Celgene sues to protect patents for blockbuster cancer drug Revlimid

Intellectual Property 2021-11-22 4:10 pm By Cindy Cameronne | Sydney

Please login to bookmark

Bristol-Myers Squib unit Celgene Corporation has sued Indian generics giant Dr Reddy’s Laboratories for allegedly threatening to infringe eight patents for its blockbuster cancer drug Revlimid, which raked in US$12 billion for the US-based company in revenue last year.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au